Welcome to our dedicated page for Unicycive Therapeutics news (Ticker: UNCY), a resource for investors and traders seeking the latest updates and insights on Unicycive Therapeutics stock.
Unicycive Therapeutics, Inc. (UNCY) is a clinical-stage biotechnology company whose news flow centers on the development and regulatory progress of kidney disease therapies. Company press releases highlight advances for its lead investigational product oxylanthanum carbonate (OLC), an oral phosphate binder for hyperphosphatemia in chronic kidney disease patients on dialysis, and for its second program UNI-494, which is intended for conditions related to acute kidney injury.
Investors following UNCY news can expect detailed updates on regulatory interactions with the U.S. Food and Drug Administration, including New Drug Application submissions, Complete Response Letters, Type A meetings, and NDA resubmissions for OLC. The company also reports on pivotal and Phase 2 clinical trial results, analyses of pill burden and phosphate control, and publications of OLC data in peer-reviewed journals such as the Clinical Journal of the American Society of Nephrology.
Unicycive’s news releases frequently cover financial results, cash runway commentary, and capital markets activities, such as at-the-market equity offerings and reverse stock split implementation, as disclosed in associated Form 8-K filings. Additional news items include participation in healthcare and investor conferences, issuance of new patents for UNI-494 and its use in chronic kidney disease, and corporate updates on Nasdaq listing compliance and legal matters, including disclosure of a purported securities class action.
This UNCY news page aggregates these company-issued updates so readers can review clinical data milestones, regulatory developments, intellectual property announcements, and financial disclosures in one place. For those tracking the progress of oxylanthanum carbonate and UNI-494, the news feed provides a chronological view of Unicycive’s communications about its kidney disease pipeline and corporate activities.
Unicycive Therapeutics, a clinical stage biotechnology firm focused on kidney disease therapies, announced that CEO Shalabh Gupta will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. A webcast link will be available on the Unicycive website's Investors section on September 13, with an archive accessible for three months. Unicycive's lead drug, Renazorb, targets hyperphosphatemia, while UNI-494 is in late preclinical development for acute kidney injury. For further details, visit www.unicycive.com.
Unicycive Therapeutics, a clinical-stage biotechnology firm focused on kidney disease treatments, disclosed its Q2 2021 financial results. The company raised $25 million from its recent IPO and plans to meet the FDA in Q4 2021 regarding its lead product Renazorb. R&D expenses increased to $0.5 million from $0.2 million year-over-year, and net loss rose to $1.1 million or $0.13 per share. The company is working on the investigational drug UNI-494 and expects significant milestones in the upcoming periods.